Answers are grounded in this paper and cite their sources.
Conflicts of interest: none declared. Sir, The National Institute for Health and Clinical Excellence (NICE) guidelines published in July 2006 advise etanercept, a TNF‐α antagonist, as a treatment for severe plaque psoriasis in patients who have not responded to other therapies.1 Patients embarking on any immunosuppressive treatment require screening for tuberculosis (TB). This has traditionally consisted of Mantoux skin testing alongside risk stratification for exposure from history.2 The problem with skin testing and screening is cross‐reactivity with the BCG vaccine, which often gives false positive results. This may lead to unnecessary chemoprophylaxis, not only delaying the start of immunosuppressive therapy but also carrying with it possible dangerous side‐effects. There are also practical difficulties in reading the Mantoux on patients with widely affected skin in severe psoriasis and the cost implications of unnecessary TB treatment. The QuantiFERON®‐TB Gold test (QFT‐G; Cellestis Ltd, Carnegie, Australia) is a novel TB enzyme‐linked immunosorbent assay, based on detection of interferon‐γ release from sensitized leucocytes exposed to the synthetic Mycobacterium tuberculosis antigens, ESAT‐6 and CFP‐10. These antigens are secreted by M. tuberculosis but are absent from BCG vaccine strains and from most nontuberculous mycobacteria. There is no cross‐reactivity in previously vaccinated patients. The test is reported to have greater sensitivity and specificity than Mantoux testing (QFG‐T: 89% and 98·1%; Mantoux: 72% and 82%).3 4–5
No takes yet. Share an insight, caveat, or question.
Desai et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: